IP Library Granted Patent US 9,724,360
Granted Patent B2
US 9,724,360 · App. 14/926,062 · Granted Aug 8, 2017

Methods for treating

Inventors: Byoung Kwon Chun (Pleasanton, CA); Michael O' Neil Hanrahan Clarke (Redwood City, CA); Edward Doerffler (Foster City, CA); Hon Chung Hui (Foster City, CA); Robert Jordan (Foster City, CA); Richard L. Mackman (Millbrae, CA); Jay P. Parrish (El Dorado Hills, CA); Adrian S. Ray (Burlingame, CA); Dustin Siegel (San Carlos, CA)
Assignee: GILEAD SCIENCES, INC.
A61K31/685A61K31/00A61K31/53A61K31/675A61K45/06C07D487/04C07D519/00C07F9/2429C07F9/65616C07H1/00C07H1/02C07H11/00C07H15/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,360
App. No.
14/926,062
Granted
Aug 8, 2017
Kind
B2
Abstract

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Claims (10)

1. A compound:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and optionally other therapeutic agents.

4. The pharmaceutical composition according to claim 3 wherein the other therapeutic agents is selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola Convalescent Plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), favipiravir (also known as T-705 or Avigan), T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), JK-05, TKM-Ebola, ZMapp, rNAPc2, VRC-EBOADC076-00-VP, OS-2966, MVA-BN filo, brincidofovir, Vaxart adenovirus vector 5-based ebola vaccine, Ad26-ZEBOV, FiloVax vaccine, GOVX-E301, GOVX-E302, ebola virus entry inhibitors (NPC1 inhibitors), rVSV-EBOV, and mixtures thereof.

5. The pharmaceutical composition according to claim 4 wherein the other therapeutic agents is ZMapp.

6. A method of treating a Filoviridae infection in a human in need thereof comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1 or a pharmaceutical composition of any one of claims 3 to 5 .

7. The method of claim 6 wherein the Filoviridae infection is an ebolavirus infection.

8. The method of claim 6 wherein the Filoviridae infection is a Marburg virus infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2016
From: CHUN, BYOUNG KWON; HANRAHAN CLARKE, MICHAEL O'NEIL; DOERFFLER, EDWARD; HUI, HON CHUNG; JORDAN, ROBERT; MACKMAN, RICHARD L.; PARRISH, JAY P.; RAY, ADRIAN S.; SIEGEL, DUSTIN
To: GILEAD SCIENCES, INC.
Reel/Frame 037554/0590 →
Continuity (3)
Provisional Application 62105619 · Jan 20, 2015
Provisional Application 62072331 · Oct 29, 2014
Related Publication 20160122374A1 · May 5, 2016